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BACKGROUND 
Although it is difficult to ascertain, it is estimated that throughout 
history have died over 200 million people because of plague.  
That is because without an effective treatment, 50–60% of 
cases of bubonic plague are fatal, while untreated septicaemic 
and pneumonic plague are invariably fatal. [1] 
 
Plague has been used as a weapon many times throughout 
history, like in 1347 when the Mongols catapulted bodies of 
infested people into Caffa or during the Second World War 
when Japan sent rice carrying Yersinia pestis. 
Yet the most disturbing precedent is the antibiotic-resistant 
Yersinia pestis that the Russians tried to develop. [2] 
 
Nowadays plague can be treated with streptomycin or 
gentamicin reducing mortality to only 1-5% of those infected.  
However, an efficient vaccine that  develops protective immune 
response is lacked. [1] [3] 
 
That raises the question of what would happen if these 
antibiotics didn’t work?  
• Create a subcutaneous vaccine capable of inducing not only humoral but also cellular response. 
• Try some different adjuvants and establish which one is the fittest for human vaccination. 
• Use viral vectors for expression of recombinant F1 and V proteins in leaves of N. benthamiana, to prove that is a rapid, 
cheap and efficient expression system. 
• Develop a vaccine that can protect humankind in case of a terrorist attack with an antibiotic-resistant Yersinia pestis. 
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• It can be expected that the control group will have fewer antibodies in serum and therefore it is also expected a higher rate of 
deaths. 
• It is expected a lower response  from Aluminium hydroxide.  
• A high level of cellular response with IL-12, QS-21 and MF59 adjuvants. 
• Better results than in other studies (fig. 4). 
 
• Determine and optimize the best suited adjuvants for the vaccine. 
• Identify flaws in the current system of vaccination  
• Provide safety to population in case of a bioterrorist attack.  
It has been decided to use a recently developed transfection technology that relies on Agrobacterium as an infective systemic 
agent that delivers deconstructed tobacco mosaic virus (TMV) viral replicons. This improved process is being used to 
simultaneously start transient gene amplification and high-level expression in all mature leaves of a plant. This technology, 
combines advantages of three biological systems: vector efficiency and efficient systemic DNA delivery of Agrobacterium, speed 
and expression of a plant RNA virus, as well as low production costs of a plant. [4] 
OBJECTIVES 
WORKING PLAN 
Infect the plant (fig. 1) 
Expression of viral vectors in 
Agrobacterium 
Subclone the genes into the 
viral vectors 
Confirm infiltration 
(fig. 2) 
Start the trials on guinea pigs 
(fig. 3)  
Construction of different 
adjuvant vaccines 
Purification of the proteins 
Ten days of viral 
expression 
EXPECTED RESULTS AND BENEFITS REFERENCES 
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Figure 3. Vaccines with the corresponding  adjuvant will be administrated to 8 guinea pigs each.  
*1: Blood sample 
*2: Trial with lethal dose 50  
Figure 4. Survival of vaccinated Hartley guinea pigs to aerosolized Y. pestis [4].  
Figure 1. Nicotiana benthamiana  infiltrated with the cultures of Agrobacterium 
Figure 2.   
A) Fragments of DNA from Untransformed and Transformed plants 
B) Southern blot analysis of transgenic lines.  Transformed  
with the integration (9,5kb). And without the integration (8kb) [5].  
 
